Investors in Newron Pharmaceuticals SPA have reacted nervously to the news that US regulators have called in the Italian drugmaker for discussions about its Rett syndrome drug, sarizotan, before pivotal data from a late-stage trial can be unblinded.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?